{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:10:51Z","timestamp":1789690251145,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","award":["648\/1996"],"award-info":[{"award-number":["648\/1996"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014805","name":"Roche Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.esmoop.2024.102943","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T19:35:37Z","timestamp":1710531337000},"page":"102943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0059-5660","authenticated-orcid":false,"given":"M.","family":"Caccese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5264-1251","authenticated-orcid":false,"given":"M.","family":"Simonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chiesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-4677","authenticated-orcid":false,"given":"E.","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Stasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Caserta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Brugnara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bennicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1612-6156","authenticated-orcid":false,"given":"P.","family":"Bini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Cuccu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Scoccianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Padovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6320-405X","authenticated-orcid":false,"given":"S.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3243-0059","authenticated-orcid":false,"given":"A.","family":"Pellerino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gregucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-1480","authenticated-orcid":false,"given":"V.","family":"Intern\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pernice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dealis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Stievano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Paiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1839-2586","authenticated-orcid":false,"given":"G.","family":"Magni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7451-8476","authenticated-orcid":false,"given":"G.L.","family":"De Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Zagonel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-2132","authenticated-orcid":false,"given":"G.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 4","key":"10.1016\/j.esmoop.2024.102943_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.102943_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102943_bib3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"9863","key":"10.1016\/j.esmoop.2024.102943_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"10064","key":"10.1016\/j.esmoop.2024.102943_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.esmoop.2024.102943_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102943_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102943_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102943_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102943_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102943_bib12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ejca.2010.01.012","article-title":"An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients","volume":"46","author":"Taphoorn","year":"2010","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.esmoop.2024.102943_bib14","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-19-4055","article-title":"Phosphorylated acetyl-CoA carboxylase is associated with clinical benefit with regorafenib in relapsed glioblastoma: REGOMA trial biomarker analysis","volume":"26","author":"Indraccolo","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102943_bib15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/neuonc\/noaa156","article-title":"A\u00a0molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib","volume":"23","author":"Santangelo","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102943_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-20417-y","article-title":"Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma","volume":"12","author":"Chiesa","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.esmoop.2024.102943_bib17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00234-023-03169-y","article-title":"Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma","volume":"65","author":"Martucci","year":"2023","journal-title":"Neuroradiology"},{"issue":"1129","key":"10.1016\/j.esmoop.2024.102943_bib18","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211018","article-title":"PET\/MR in recurrent glioblastoma patients treated with regorafenib: [18F]FET and DWI-ADC for response assessment and survival prediction","volume":"95","author":"Lombardi","year":"2022","journal-title":"Br J Radiol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.102943_bib19","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/neuonc\/noz071","article-title":"Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis","volume":"21","author":"Tzaridis","year":"2019","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102943_bib20","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00432-019-02868-5","article-title":"Regorafenib in patients with recurrent high-grade astrocytoma","volume":"145","author":"Kebir","year":"2019","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102943_bib21","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1007\/s10143-022-01826-z","article-title":"Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity","volume":"45","author":"Treiber","year":"2022","journal-title":"Neurosurg Rev"},{"issue":"12","key":"10.1016\/j.esmoop.2024.102943_bib22","first-page":"2031","article-title":"Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients","volume":"8","author":"Zeiner","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2024.102943_bib23","doi-asserted-by":"crossref","first-page":"v97","DOI":"10.1093\/neuonc\/noad179.0366","article-title":"CTNI-85. GBM agile platform trial for newly diagnosed and recurrent GBM: results of first experimental arm, regorafenib","volume":"25","author":"Wen","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.esmoop.2024.102943_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2024.102943_bib25","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.esmoop.2024.102943_bib26","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102943_bib27","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.3390\/cancers13112773","article-title":"Depatuxizumab mafodotin (Depatux-M) plus temozolomide in recurrent glioblastoma patients: real-world experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)","volume":"13","author":"Padovan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102943_bib28","first-page":"CD013579","article-title":"Treatment options for progression or recurrence of glioblastoma: a network meta-analysis","volume":"5","author":"McBain","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.esmoop.2024.102943_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.critrevonc.2017.01.018","article-title":"Effectiveness of antiangiogenic drugs in glioblastoma patients: a systematic review and meta-analysis of randomized clinical trials","volume":"111","author":"Lombardi","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"21","key":"10.1016\/j.esmoop.2024.102943_bib30","first-page":"6480","article-title":"Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis","volume":"25","author":"Zhang","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.esmoop.2024.102943_bib31","article-title":"Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.102943_bib32","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102943_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2021.06.055","article-title":"Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial)","volume":"155","author":"Lombardi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102943_bib34","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102943_bib35","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1002\/hsr2.114","article-title":"Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice","volume":"2","author":"Desjardins","year":"2019","journal-title":"Health Sci Rep"},{"issue":"18","key":"10.1016\/j.esmoop.2024.102943_bib36","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.3390\/cancers13184731","article-title":"Regorafenib in recurrent glioblastoma patients: a large and monocentric real-life study","volume":"13","author":"Lombardi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102943_bib37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11060-023-04356-w","article-title":"Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study","volume":"163","author":"Caccese","year":"2023","journal-title":"J\u00a0Neurooncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102943_bib38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/CAD.0b013e32835aa5fd","article-title":"Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature","volume":"24","author":"Lombardi","year":"2013","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102943_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/07357907.2015.1088948","article-title":"Angiopoietin-2 may be involved in the resistance to bevacizumab in recurrent glioblastoma","volume":"34","author":"Labussiere","year":"2016","journal-title":"Cancer Invest"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102943_bib40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11060-022-04155-9","article-title":"Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?","volume":"160","author":"Rud\u00e0","year":"2022","journal-title":"J\u00a0Neurooncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924007117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924007117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:31:23Z","timestamp":1761856283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924007117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2059702924007117"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102943","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102943"}}